Item 8.01 Other Events.
On January 20, 2023, Tenax Therapeutics, Inc. (the "Company") received written
notification from the Nasdaq Stock Market LLC ("Nasdaq") confirming that the
Company's common stock had a closing price of $1.00 or greater for the ten
consecutive trading days from January 5, 2023 to January 19, 2023 and that as a
result the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2)
(the "Bid Price Rule") and that the matter is now closed.
As previously reported, on February 17, 2022, Nasdaq notified the Company that
for the last 30 consecutive business days, the bid price for the Company's
common stock had closed below the minimum $1.00 per share requirement for
continued inclusion on the Nasdaq Capital Market pursuant to the Bid Price Rule.
On August17, 2022, the Company received formal notice that Nasdaq had granted
the Company's request for an extension through February 13, 2023 to evidence
compliance with the Bid Price Rule.
2
© Edgar Online, source Glimpses
TENAX THERAPEUTICS, INC. 
